These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25521641)

  • 41. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
    Simoens S; Decramer M; Laekeman G
    Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.
    Shiroiwa T
    Int J Technol Assess Health Care; 2020 Jun; 36(3):270-276. PubMed ID: 32419677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Effects of the New Methodology Application on the Method of Pricing of Drugs-The Case of the Republic of Macedonia.
    Zareski R; Kapedanovska Nestorovska A; Grozdanova A; Dimitrova B; Suturkova LJ; Sterjev Z
    Value Health Reg Issues; 2016 Sep; 10():19-28. PubMed ID: 27881273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reference Pricing Changes The 'Choice Architecture' Of Health Care For Consumers.
    Robinson JC; Brown TT; Whaley C
    Health Aff (Millwood); 2017 Mar; 36(3):524-530. PubMed ID: 28264955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Why is big Pharma getting out of antibacterial drug discovery?
    Projan SJ
    Curr Opin Microbiol; 2003 Oct; 6(5):427-30. PubMed ID: 14572532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
    Pichon-Riviere A; Garay OU; Augustovski F; Vallejos C; Huayanay L; Bueno Mdel P; Rodriguez A; de Andrade CJ; Buendía JA; Drummond M
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):2-11. PubMed ID: 25989703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Is the price of cancer drugs related to the cost of develo-pment and production or to the economic value of their clincal efficacy?].
    Russi A; Serena M; Palozzo AC
    Recenti Prog Med; 2016 Apr; 107(4):181-5. PubMed ID: 27093327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland.
    Koskinen H; Mikkola H; Saastamoinen LK; Ahola E; Martikainen JE
    Value Health; 2015 Dec; 18(8):1105-12. PubMed ID: 26686797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Opportunistic pricing: a new scourge, a new call for action.
    Proj Inf Perspect; 1998 Dec; (26):1-5. PubMed ID: 11366486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
    Badía X; Brosa M; Tellado JM
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.